Broadcast Date: June 13th, 2017
Time: 11:00 am ET, 8:00 am PT
Innovation continues to be a primary driver of value in pharmaceutical research. However, simultaneously, research budgets are coming under ever-increasing pressure. As a consequence, pharma is moving toward a so-called open research model, one that dispenses with recurrent fixed costs in favor of a more flexible and dynamic external “spend.” By adopting this model, pharma could tap into innovation outside their walls. In this webinar, case studies will be presented highlighting the value of such collaborations, while focusing on discovery campaigns that employ highly relevant functional assays.
Describing how to use an integrated approach that fuses the disciplines of in silico drug design, medicinal chemistry, and discovery biology, the presenters will demonstrate how their unique approach helped them meet key goals during the early discovery process, as well as which factors contributed to their subsequent successes. Making medicines these days cannot be done in isolation. And the story presented in this webinar shows an excellent example of a partnership in action for developing new treatments to support unmet pharmaceutical needs.
Who Should Attend
- Drug discovery scientists
- Cardiovascular disease investigators
- Medicinal chemists
- Drug development researchers
- CEO’s and founders of virtual and start-up companies
You Will Learn
- Recent advances in the early drug discovery process
- The importance of tight integration of disciplines in addressing challenging targets
- How collaboration in early discovery can create high-quality advanced leads
Produced with support from:
Robert S. McDowell, M.D., Ph.D.
Senior Vice President, Drug Discovery,
Kenneth F. Wertman, Ph.D.
Senior Vice President,